TRANSBIOTICS
Dead / Abandoned — Abandoned — no statement of use filed (as of 25 Nov 2019)
What this means for you
This application is over — abandoned 25 Nov 2019. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 87724721
- Mark type
- Stylized text
- Filed
- 18 Dec 2017
- Published for opposition
- 28 Aug 2018
- Abandoned
- 25 Nov 2019
- Attorney of record
- David S. Kerr
Goods and services
- Class 001 — Chemicals: Cultures of microorganisms other than for medical and veterinary use, namely, genetically modified microorganisms that express interfering molecules that inhibit the expression of target genes; Cultures of microorganisms other than for medical or veterinary use, namely, genetically modified microorganisms for use in therapeutic treatment of pathogens in plants, namely, microorganisms that express RNA-based therapeutic agents that inhibit the expression of target pathogen genes; Cultures of microorganisms other than for medical or veterinary use, namely, probiotic compositions for use in therapeutic treatment of pathogens in plants, namely, genetically engineered bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Probiotic compositions use as ingredients for food and beverages, namely, genetically engineered probiotic bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Probiotic compositions for use as ingredients for food and beverages, namely, genetically modified probiotic bacteria configured to produce bioavailable nutritional compounds; Cultures of microorganisms for medical or agricultural use, namely, genetically modified endophytic bacteria for use in therapeutic treatment of pathogens in plants
- Class 005 — Pharmaceuticals: Cultures of microorganisms for medical and veterinary use, namely, genetically modified microorganisms that express interfering molecules that inhibit the expression of target genes; Biological preparations for the treatment of infectious diseases in animals, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target animal pathogen genes; Biological preparations for the treatment of infectious diseases in plants, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target plant pathogen genes; Biological preparations for the treatment of viral infections in plants, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target viral pathogen genes; Biological preparations for the treatment of bacterial infections in animals, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target bacterial pathogen genes; Biological preparations for the treatment of fungal diseases, namely, biotheraputics consisting of genetically modified microorganisms that express RNA-based therapeutic agents that inhibit the expression of target fungal pathogen genes; Cultures of microorganisms for medical or veterinary use, namely, genetically modified microorganisms for use in therapeutic treatment of pathogens in animals, namely, microorganisms that express RNA-based therapeutic agents that inhibit the expression of target pathogen genes; Probiotic preparations for medical or veterinary use, namely, probiotic compositions for use in therapeutic treatment of pathogens in animals, namely, genetically engineered bacteria that express RNA-based therapeutic agents to inhibit the expression of target pathogen genes; Cultures of microorganisms for medical or veterinary use, namely, genetically modified enteric bacteria for use in therapeutic treatment of pathogens in animals; Medical, biological and pharmaceutical preparations for the prevention and treatment of infectious diseases in plants and animals; biological RNA-based therapeutic agents for the prevention and treatment of infectious diseases in plants and animals; Cultures of microorganisms for medical or veterinary use, namely, biological RNA-based therapeutic agents that inhibit the expression of target genes in plant pests and herbivores
Owner
- PEBBLE LABS INC., SANTA FE, NM, US
- Pebble Labs, Inc., Los Alamos, NM, CA
- Pebble Labs, Inc., Los Alamos, NM, CA
Prosecution history
- 25 Nov 2019 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 25 Nov 2019 — ABANDONMENT - NO USE STATEMENT FILED
- 09 Oct 2019 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 25 Apr 2019 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 Apr 2019 — SOU EXTENSION 1 GRANTED
- 23 Apr 2019 — SOU EXTENSION 1 FILED
- 23 Apr 2019 — SOU TEAS EXTENSION RECEIVED
- 23 Oct 2018 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 28 Aug 2018 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 28 Aug 2018 — PUBLISHED FOR OPPOSITION
- 08 Aug 2018 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Jul 2018 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Jul 2018 — EXAMINER'S AMENDMENT ENTERED
- 23 Jul 2018 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 23 Jul 2018 — EXAMINERS AMENDMENT E-MAILED